European Commission approves Roche ’s Tecentriq in combination with Avastin and chemotherapy for the initial treatment of people with a specific type of metastatic lung cancer
Roche today announced that the European Commission has approved and granted marketing authorisation for Tecentriq ® (atezolizumab) in combination with Avastin® (bevacizumab), paclitaxel and carboplatin, for the first-line treatment of adults with metastatic non-squamous non-small cell lung cancer (NSCLC).
Source: Roche Media News - Category: Pharmaceuticals Source Type: news
More News: Avastin | Cancer | Cancer & Oncology | Chemotherapy | Lung Cancer | Marketing | Non-Small Cell Lung Cancer | Pharmaceuticals